(Q33859922)

29 July 2017

1 reference

title

Cyclophosphamide and etoposide for non-small cell and small cell lung cancer (English)

1 reference

29 July 2017

1 reference

Grunberg SM

1

1 reference

29 July 2017

publication date

1 January 1999

1 reference

29 July 2017

1 reference

29 July 2017

volume

58 Suppl 3

1 reference

29 July 2017

page(s)

11-15

1 reference

VP 16-213 (VP 16) and cyclophosphamide in the treatment of primitive lung cancer in phase M 1

29 July 2017

cites work

1 reference

12 December 2020

Combination chemotherapy with 4'Demethylepipodophyllotoxin 9-(4,6-0-ethylidene-beta-D-glucopyranoside), VP 16-213 (NSC 141540) in L1210 leukemia

1 reference

12 December 2020

Phase I trial of intravenous carboplatin added to oral etoposide and oral cyclophosphamide for stage IV non-small cell lung cancer

1 reference

12 December 2020

Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide

1 reference

12 December 2020

Epipodophyllotoxin-related leukemia. Identification of a new subset of secondary leukemia

1 reference

12 December 2020

Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy.

1 reference

12 December 2020

VP-16 plus cyclophosphamide in the treatment of advanced lung cancer

1 reference

12 December 2020

Single-agent oral etoposide for elderly small cell lung cancer patients.

1 reference

12 December 2020

A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer

1 reference

12 December 2020

Phase II study of the oral cyclophosphamide and oral etoposide combination in hormone-refractory prostate carcinoma patients

1 reference

12 December 2020

Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multicentre randomised trial. Medical Research Council Lung Cancer Working Party.

1 reference

12 December 2020

1 reference

12 December 2020

Risk of therapy-related leukaemia and preleukaemia after Hodgkin's disease. Relation to age, cumulative dose of alkylating agents, and time from chemotherapy.

1 reference

12 December 2020

Combination chemotherapy with oral etoposide plus intravenous cyclophosphamide in liver metastases of breast cancer

1 reference

12 December 2020

VP16-213 and cyclophosphamide in advanced breast cancer. A phase II study.

1 reference

12 December 2020

An analysis of the outcomes of treatment of small cell lung cancer in the elderly

1 reference

12 December 2020

Combination Chemotherapy as an Adjuvant Treatment in Operable Breast Cancer

1 reference

12 December 2020

Re: Five-Day Oral Etoposide Treatment for Advanced Small-Cell Lung Cancer: Randomized Comparison With Intravenous Chemotherapy

1 reference

12 December 2020

Etoposide, Ifosfamide, and Cisplatin in Extensive Small Cell Lung Cancer

1 reference

12 December 2020

High frequency of etoposide (VP-16)-related secondary leukemia in children with non-Hodgkin's lymphoma

1 reference

12 December 2020

Extended administration of oral etoposide and oral cyclophosphamide for the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study

1 reference

12 December 2020

Bioavailability of low-dose oral etoposide

1 reference

12 December 2020

10.2165/00003495-199958003-00002

Identifiers

DOI

0 references

Dimensions Publication ID

1003203881

0 references

1 reference